Oncology

News

Astellas claims EU okay for first claudin 18.2 cancer drug

The EU has followed Japan and GB in approving Astellas' first-to-market claudin 18.2-targeted therapy Vyloy, clearing it for gastric and gastroesophageal junction (GEJ) cancer.

News

Sanofi's Sarclisa gets one up on rival Darzalex in myeloma

Sanofi's Sarclisa has been an also-ran in the anti-CD38 antibody class behind Johnson & Johnson and Genmab's blockbuster Darzalex, but now has a chance to steal some of the spotlight.

News

J&J nets another key approval for blockbuster hope Rybrevant

Johnson & Johnson's target of $5 billion in sales for its EGFRxMET bispecific antibody Rybrevant has moved a step closer, after a new FDA approval in non-small cell lung cancer (NSCLC).

News

Job losses loom at Achilles as TIL therapy platform is cut

Employees at Achilles Therapeutics are bracing themselves for job losses after the UK biotech announced that it is dropping its R&D in tumour-infiltrating lymphocyte (TIL) therapies for

News

Lilly on alert as new Kisqali approval threatens Verzenio

Novartis' CDK4/6 inhibitor Kisqali has claimed a broad FDA approval in early breast cancer that could give it an edge over class rival Verzenio from Eli Lilly.

News

After FDA no, MSD/Daiichi post new data with lung cancer ADC

MSD and Daiichi Sankyo's patritumab deruxtecan hit its main objective in a phase 3 lung cancer study that reinforces its potential as a new treatment option for patients after first-line tr

Astellas claims EU okay for first claudin 18.2 cancer drug

Sanofi's Sarclisa gets one up on rival Darzalex in myeloma

J&J nets another key approval for blockbuster hope Rybrevant

Job losses loom at Achilles as TIL therapy platform is cut

Lilly on alert as new Kisqali approval threatens Verzenio

After FDA no, MSD/Daiichi post new data with lung cancer ADC

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

Oncology

Editor's Picks